MedTrace Logo

Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis

NCT00301509 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2006-03-13

No results posted yet for this study

Summary

To evaluate:

1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study.
2. safety and efficacy of antiviral therapy in this population by using a statistically significally number of patients as controls.

Conditions

  • Liver Cirrhosis, Experimental

Interventions

DRUG

peginterferon and ribavirin

Sponsors & Collaborators

  • Casa Sollievo della Sofferenza IRCCS

    lead OTHER

Principal Investigators

  • Angelo Andriulli, Chief · CSS

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-01-31
Completion
2005-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00301509 on ClinicalTrials.gov